pNGVL4aCRTE6E7L2

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NamepNGVL4aCRTE6E7L2
Drug Alias NamepNGVL4aCRTE6E7L2 DNA vaccineNaked pNGVL4aCRTE6E7L2 DNA plasmidPVX-6
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > DNA vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsSquamous Intraepithelial LesionsAtypical Squamous Cells of the CervixCervical Intraepithelial Neoplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Alabama At BirminghamJohns Hopkins UniversityPapivax Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesJohns Hopkins UniversityNational Cancer InstituteUniversity Of Alabama At Birmingham
Inactive CompaniesN/A
Active IndicationsSquamous Intraepithelial LesionsAtypical Squamous Cells of the CervixCervical Intraepithelial Neoplasia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A